Use Of Viral IL-6 To Modulate Monocyte Differentiation To Boost Anti-Tumor Immunity

Tech ID: 33317 / UC Case 2022-582-0

**ABSTRACT**

Researchers at the University of California, Davis have developed a virally derived homolog to increase the inflammatory response desirable in cancer immunotherapy.

**FULL DESCRIPTION**

Researchers at the University of California Davis have developed the use of a virally derived homolog of interleukin-6 (vIL-6) to increase the inflammatory response desirable in cancer immunotherapy. The technology promotes dendritic cell differentiation and M1 macrophage differentiation from monocytes, unlike human IL-6, and doesn't trigger anti-inflammatory negative feedback mechanisms. The technology includes the RNA- and viral vector-based delivery of vIL-6-encoding nucleic acids.

Unlike IL-6, vIL-6 does not trigger negative feedback regulation, thus providing a unique benefit when it's used therapeutically as it does not limit its own efficacy by self-downregulation. This new technology aims to enhance cancer therapy by combining the administration of vIL-6 with an anti-cancer therapeutic agent, especially an anti-cancer immunotherapeutic agent.

**APPLICATIONS**

- Development of new medication and treatments for cancer
- Potential use in research and development in the medical and pharmaceutical industry
- Useful in the field of cancer therapeutics, specifically in immunotherapy
- Potential application in the manufacturing of cell culture mediums
- May be incorporated into various delivery systems such as viral vector-based delivery, liposomal formulations, transdermal patches, etc for treating cancer

**FEATURES/BENEFITS**

- Increases the inflammatory response desirable in cancer therapies
- Promotes dendritic cell differentiation and M1 macrophage differentiation
- Utilizes RNA- and viral vector-based delivery for effective implementation
- Does not self-downregulate which is an issue with existing therapies that are limited by negative feedback mechanisms
- Can be applied in various formats such as protein form or nucleic acid form
- Potential supplement for cell culture to enhance the recovery and efficacy of dendritic cells

**PATENT STATUS**

<table>
<thead>
<tr>
<th>Country</th>
<th>Type</th>
<th>Number</th>
<th>Dated</th>
<th>Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent Cooperation Treaty</td>
<td>Published Application</td>
<td>WO 2023/200897</td>
<td>10/19/2023</td>
<td>2022-582</td>
</tr>
</tbody>
</table>

Additional Patent Pending

**INVENTORS**

- Izumiya, Yoshihiro
- Shimoda, Michiko

**CATEGORIZED AS**

- Medical
- Disease: Cancer
- Gene Therapy
- New Chemical Entities, Drug Leads
- Therapeutics
- Research Tools
- Nucleic Acids/DNA/RNA
- Protein Synthesis

**RELATED CASES**

- 2022-582-0

**ADDITIONAL TECHNOLOGIES BY THESE INVENTORS**

- Transcription Active Complex Targeting Cancer Drug From Viral Protein Sequence
- CHD4 Targeting Peptide Isolated From Viral Protein For Cancer Therapeutics
- Cellular Protein CDH4 Inhibiting Peptide